C-Type Natriuretic Peptide Derivatives: Orthopaedic Implications in Achondroplasia

The recent development of C-type natriuretic peptide (CNP) analogs to increase growth velocity in achondroplasia is now being used alongside limb lengthening procedures. Animal studies have shown that CNP analogs may affect bone density and the speed of callus consolidation during fracture healing. Although achondroplasia is primarily associated with a defect in endochondral ossification, pharmaceutical treatments for the condition may also influence intramembranous ossification. The availability of these nonsurgical treatments warrants further investigation into their potential impact on surgical risks and outcomes. Data suggest that they may affect bone quality, healing, and anatomical parameters such as medullary canal area, which could influence treatment decisions and surgical planning. This review aims to synthesize current evidence on CNP analog pathways and their intersection with biological processes involved in the surgical management of children with achondroplasia.

(1)CNP-NPR-B activation boosts bone mineral density and improves fracture healing in mouse models.(2)CNP analogs are now used to treat achondroplasia, which could affect surgical limb lengthening procedures.(3)Clinicians should consider reporting bone healing features like callus quality and consolidation indices during bone healing to enhance our understanding of how pharmacotherapeutics may affect surgical outcomes.